UPM-Kymmene Oyj (0NV5)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 24.44 |
|---|---|
| 52-week range | 22.12 – 27.94 |
| Return, 1 month / 3 months | −6.1% / +1.0% |
| Return, 1 year / 3 years | +11.3% / −9.1% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 23.3% |
| Worst drawdown (1 year) | -19.8% |
| Average daily value traded | 3.96M EUR |
| Dividend yield | 3.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
UPM-Kymmene Oyj is a Finnish forest products company based in Helsinki. It makes pulp, paper and paperboard, plywood and other wood products, and supplies self-adhesive label materials through its Raflatac business. The company also produces biofuels and operates in energy and biochemicals. Its customers include publishers, printers, packaging converters, label makers, construction firms and industrial manufacturers, and its operations span Europe, North America, Asia and South America.
UPM-Kymmene Oyj trades under the code 0NV5 on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
UPM-Kymmene Oyj (0NV5) trades on the London Exchange in UK. It last closed at EUR 24.44 on 22 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 1,521 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.3% and over the last three months it rose 1.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -2.0% | ||
| From 52-week high | -12.1% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 1.0% | ||
| 6-month return | -7.4% | ||
| 12-month return, skipping the last month | 18.5% | ||
| Stability (higher is calmer) | 76 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.8% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.96M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.1% | ||
| Years with dividends | 4 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.3% |
|---|---|
| 1 month | −6.1% |
| 3 months | +1.0% |
| 6 months | −7.4% |
| 1 year | +11.3% |
| 3 years | −9.1% |
| 5 years | −3.4% |
Signals
| 50-day / 200-day average | 24.69 / 24.94 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Oct 2025 | EUR 0.7500 |
| 28 Mar 2025 | EUR 0.7500 |
| 30 Oct 2024 | EUR 0.7500 |
| 5 Apr 2024 | EUR 0.7500 |
| 25 Oct 2023 | EUR 0.7500 |
| 13 Apr 2023 | EUR 0.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.